These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 23913215)
21. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Stewart JJ; White JT; Yan X; Collins S; Drescher CW; Urban ND; Hood L; Lin B Mol Cell Proteomics; 2006 Mar; 5(3):433-43. PubMed ID: 16319398 [TBL] [Abstract][Full Text] [Related]
22. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948 [TBL] [Abstract][Full Text] [Related]
23. Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR. Ong PS; Chan SY; Ho PC Eur J Pharm Sci; 2012 Feb; 45(3):367-78. PubMed ID: 22178533 [TBL] [Abstract][Full Text] [Related]
24. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer]. Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133 [TBL] [Abstract][Full Text] [Related]
25. Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: involvement of p38 MAPK activation. Zhang B; Wang X; Cai F; Chen W; Loesch U; Zhong XY Oncol Rep; 2013 Apr; 29(4):1371-8. PubMed ID: 23338561 [TBL] [Abstract][Full Text] [Related]
26. [Establishment of 5 resistant ovarian cancer cell strains and expression of resistance-related genes]. Luan YZ; Li L; Li DR; Zhang W; Tang BJ Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):403-7. PubMed ID: 15312326 [TBL] [Abstract][Full Text] [Related]
27. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways. Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949 [TBL] [Abstract][Full Text] [Related]
28. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection. Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915 [TBL] [Abstract][Full Text] [Related]
29. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Jiao JW; Wen F Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580 [TBL] [Abstract][Full Text] [Related]
30. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771 [TBL] [Abstract][Full Text] [Related]
31. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness. Pavan S; Olivero M; Corà D; Di Renzo MF Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474 [TBL] [Abstract][Full Text] [Related]
32. Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. Takano M; Kudo K; Goto T; Yamamoto K; Kita T; Kikuchi Y Hum Cell; 2001 Dec; 14(4):267-71. PubMed ID: 11925927 [TBL] [Abstract][Full Text] [Related]
33. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035 [TBL] [Abstract][Full Text] [Related]
34. Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling. Koch M; Krieger ML; Stölting D; Brenner N; Beier M; Jaehde U; Wiese M; Royer HD; Bendas G Biochem Pharmacol; 2013 Apr; 85(8):1077-90. PubMed ID: 23396090 [TBL] [Abstract][Full Text] [Related]
35. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Yan XD; Li M; Yuan Y; Mao N; Pan LY Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060 [TBL] [Abstract][Full Text] [Related]
36. Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing. Takenaka M; Saito M; Iwakawa R; Yanaihara N; Saito M; Kato M; Ichikawa H; Shibata T; Yokota J; Okamoto A; Kohno T Int J Oncol; 2015; 46(6):2389-98. PubMed ID: 25846456 [TBL] [Abstract][Full Text] [Related]
37. Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin. Gaponova AV; Deneka AY; Beck TN; Liu H; Andrianov G; Nikonova AS; Nicolas E; Einarson MB; Golemis EA; Serebriiskii IG Oncotarget; 2017 Mar; 8(12):19156-19171. PubMed ID: 27863405 [TBL] [Abstract][Full Text] [Related]
38. Verifying the markers of ovarian cancer using RNA-seq data. Liu T; Yu N; Ding F; Wang S; Li S; Zhang X; Sun X; Chen Y; Liu P Mol Med Rep; 2015 Jul; 12(1):1125-30. PubMed ID: 25776533 [TBL] [Abstract][Full Text] [Related]
39. Transcriptome analysis. Stahl F; Hitzmann B; Mutz K; Landgrebe D; Lübbecke M; Kasper C; Walter J; Scheper T Adv Biochem Eng Biotechnol; 2012; 127():1-25. PubMed ID: 21952979 [TBL] [Abstract][Full Text] [Related]